Key result
Clopidogrel, heparin, and hirudin prolong arterioarterial shunt patency, whereas aspirin shows no benefit.
Why the study?
A rat thrombosis model with controlled arterial flow and collagen-coated surface was developed to assess the efficacy of antithrombotic drugs and discriminate their mechanisms.
Do antithrombotic agents (aspirin, clopidogrel, heparin, r-hirudin) prolong shunt patency and reduce thrombus formation in a rat arterioarterial shunt model?
Population
Rats with collagen coated arterioarterial shunt between primitive carotids
Comparison
Aspirin, clopidogrel (50 mg/kg), heparin (500 U/kg), and r-hirudin effects on thrombosis
Design
Experimental thrombosis model in rats with dynamic thrombus monitoring
Follow-up
Duration of shunt patency measured in seconds to hours
Authors
Loading...
Establishes a rat shunt model discriminating antiplatelet vs anticoagulant effects; leaves open translation to clinical arteriovenous access.
Do antithrombotic agents (aspirin, clopidogrel, heparin, r-hirudin) prolong shunt patency and reduce thrombus formation in a rat arterioarterial shunt model?
This novel rat arterioarterial shunt model effectively discriminates between antiplatelet and anticoagulant mechanisms, demonstrating significant antithrombotic efficacy for clopidogrel, heparin, and hirudin, but not aspirin.
Freund et al. (1993) studied Arterial thrombosis. Antithrombotic agents (aspirin, clopidogrel, heparin, r-hirudin) vs. Control / each other was evaluated on Patency duration of the shunt. In a rat arterioarterial thrombosis model, clopidogrel, heparin, and hirudin significantly prolonged shunt patency, whereas aspirin was inactive.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: